InvestSMART

Argenica Therapeutics Limited (ASX: AGN) - Share Price

Current share price for AGN : $0.205 0.01 (5.13%)+

Argenica Therapeutics Limited (AGN) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a Company engaged in research and development of a neuroprotective therapeutic drug. Its neuroprotective peptide candidate, ARG-007, has been demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE).

AGN General Information +

ASX Code AGN
Website N/A
Industry/Sector Pharmaceuticals
Market Cap ($M) 26
AGN Share Price $0.205
Day High $0.215
Day Low $0.205
Last Close $0.195
AGN Share Price Movement $0.01 ( 5.13% )
Prices as at 16:40, 24 Aug 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Argenica Therapeutics Limited (AGN) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Argenica Therapeutics Limited (AGN) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Argenica Therapeutics Limited (AGN) price-sensitive announcements

AGN - Quarterly Activities/Appendix 4C Cash Flow Report
Argenica Therapeutics Limited, an Australian biotechnology company, is focused on developi
Argenica Therapeutics Limited (AGN)
24 Jul 2026 | 9:18 AM
AGN - ARG007 Shows Significant Neuroprotection in Concussion Study
Argenica Therapeutics Limited announced promising preclinical efficacy data for its drug c
Argenica Therapeutics Limited (AGN)
16 Jul 2026 | 8:27 AM
AGN - ARG007 (Xaranetide) Completes All Three FDA Requested Assays
Argenica Therapeutics Limited has announced the successful completion of the final FDA req
Argenica Therapeutics Limited (AGN)
11 Jun 2026 | 8:33 AM
AGN - WHO Confirms Xaranetide as INN for ARG-007
Argenica Therapeutics Limited, an Australian biotechnology company, announced that the Wor
Argenica Therapeutics Limited (AGN)
10 Jun 2026 | 8:19 AM

Argenica Therapeutics Limited (AGN) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Argenica Therapeutics Limited (AGN)
ORDINARY FULLY PAID
 Health Care $26 Notification of cessation of securities - AGN 13 Aug 2026 5:32PM $0.170 $0.205 risen by 20.59%
Argenica Therapeutics Limited (AGN)
ORDINARY FULLY PAID
 Health Care $26 Investor Presentation - Techknow Conference 27 Jul 2026 9:13AM $0.155 $0.205 risen by 32.26%
Argenica Therapeutics Limited (AGN)
ORDINARY FULLY PAID
 Health Care $26 Quarterly Activities/Appendix 4C Cash Flow Report 24 Jul 2026 9:18AM $0.150 $0.205 risen by 36.67%
Argenica Therapeutics Limited (AGN)
ORDINARY FULLY PAID
 Health Care $26 ARG007 Shows Significant Neuroprotection in Concussion Study 16 Jul 2026 8:27AM $0.140 $0.205 risen by 46.43%
Argenica Therapeutics Limited (AGN)
ORDINARY FULLY PAID
 Health Care $26 Investor Webinar 11 Jun 2026 8:33AM $0.110 $0.205 risen by 86.36%
Argenica Therapeutics Limited (AGN)
ORDINARY FULLY PAID
 Health Care $26 Investor Presentation 11 Jun 2026 8:33AM $0.110 $0.205 risen by 86.36%

AGN Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A -$7.17 -$5.60 6.40% 0.00 0.00 0.00% 0.0%
2024A -$5.48 -$5.30 -4.00% 0.00 0.00 0.00% 0.0%
2023A -$4.82 -$5.50 -0.50% 0.00 0.00 0.00% 0.0%

AGN Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 A 2025 A 2023 A 2024 A 2025 A 2023 A 2024 A 2025 A
Argenica Therapeutics Limited (AGN) $28M 0.0644 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Clarity Pharmaceuticals Ltd (CU6) $977M 0.3002 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Neuren Pharmaceuticals Limited (NEU) $2,934M -0.7857 0.2462 0.9655 99.4413 79.7931 40.5965 0.00% 0.00% 0.00%

AGN Directors

Name Position Start Date
Dr Liz Dallimore Chief Executive Officer, Managing Director 4 Apr 2022
Dr Jeannie(Jeannette) Joughin Non-Executive Director 2 Dec 2024
Dr Mark Etherton Non-Executive Director 17 Sep 2024

Argenica Therapeutics Limited (AGN) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
14 Aug 2024 ANGUS, Dianne Issued Options 500,000 $0.275 $137,727.000
8 Aug 2024 BUDGE, Terrence (Terry) Cancelled Options 181,818 $1.000 $181,818.000
8 Aug 2024 DALLIMORE, Liz Cancelled Options 909,091 $0.825 $750,000.000

See all changes in directors' interest & trades for Argenica Therapeutics Limited (AGN) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

AGN Management

Name Position
Emma Waldon Chief Financial Officer,Company Secretary

AGN Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Argenica Therapeutics Limited (AGN). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
7,835,976 (6.10%) Neil Delroy

AGN Calendar of Events

Date Event
10 February 2027 Report (Interim)
27 August 2026 Report (Annual)
27 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.